Gastroenteritis News and Research

RSS

Gastroenteritis (also known as gastro, gastric flu, and stomach flu) refers to inflammation of the gastrointestinal tract, involving both the stomach and the small intestine and resulting in acute diarrhea. The inflammation is caused most often by infection with certain viruses, less often by bacteria or their toxins, parasites, or adverse reaction to something in the diet or medication.

Breastfeeding: ADA position paper details health benefits for both infants and mothers

The American Dietetic Association has released an updated position paper on breastfeeding that details health benefits for both infants and mothers and encourages promotion of breastfeeding whenever possible.

4 Nov 2009

Interim data from Schering-Plough's narlaprevir Phase IIa study

Schering-Plough Corporation reported that interim results from an ongoing Phase IIa study of narlaprevir (SCH 900518), its investigational, once-daily protease inhibitor, demonstrated potent antiviral activity in treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1.

3 Nov 2009

Medela to host Virtual Human Milk Collection Campaign

Medela today announced it will host a Virtual Human Milk (breastmilk) Collection Campaign in honor of the March of Dimes' National Prematurity Awareness Month and the thousands of dedicated Neonatal healthcare professionals nationwide.

2 Nov 2009

Schering-Plough receives FDA complete response letter regarding PEGINTRON

Schering-Plough Corp. announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter to the company's supplemental Biologics License Application regarding PEGINTRON® (pegylated interferon alfa-2b) for the adjuvant treatment of patients with stage III malignant melanoma after complete lymphadenectomy.

31 Oct 2009

Researchers explore link between workplace stress and exposure on GI disorders

In two new studies, presented at the American College of Gastroenterology's (ACG) 74th Annual Scientific meeting in San Diego, researchers explored the connection between high stress, high exposure occupations and long-term gastrointestinal disorders.

27 Oct 2009

Merck's sales increases by 2% in third quarter 2009

Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.

22 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).

19 Oct 2009

WHO, UNICEF publish plan to reduce childhood diarrhea deaths

The WHO and UNICEF have released a seven-point treatment and prevention plan to reduce the number of children around the world who die from diarrhea, the BBC reports (10/14). BMJ News writes, "Every year 1.5 million children aged under 5 years die from diarrhoea, more than 80% of them in Africa and south Asia" (Zarocostas, 10/14).

19 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

News outlets examines health impact of disasters in Indonesia, Samoa, Philippines

In Indonesia, "[r]escue workers called off the search Monday for life under the rubble left by a massive earthquake, focusing instead on bringing aid to survivors," the Agence France-Presse reports. "The United Nations has said at least 1,100 people were killed in the disaster, but estimates of the final toll range up to 5,000. The official toll stood at 650 dead and 672 missing, according to the health ministry," the news service writes (Belford, 10/5).

6 Oct 2009

Baxter launches HYLENEX recombinant for pediatric rehydration at the 2009 ACEP

Baxter International Inc. today announced the commercial launch of HYLENEX recombinant (hyaluronidase human injection) for use in pediatric rehydration at the 2009 American College of Emergency Physicians (ACEP) scientific assembly (Boston). HYLENEX, an enzyme, allows fluids to be administered under the skin (subcutaneously) rather than through a vein.

From Baxter International Inc. 5 Oct 2009

Researchers screen decades-old frozen infant stool samples to detect norovirus

A search through decades-old frozen infant stool samples has yielded rich dividends for scientists from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

3 Oct 2009

Photosynthesis can contribute to bacterial infiltration in fresh produce

Exposure to light and possibly photosynthesis itself could be helping disease-causing bacteria to be internalized by lettuce leaves, making them impervious to washing, according to research published in the October issue of the journal Applied and Environmental Microbiology.

29 Sep 2009

International Medica Foundation sponsors rotavirus vaccine trial in Ghana

More than half a million children – or 1,400 to 1,600 each day – die from rotavirus, the most common cause of severe childhood diarrhea. Almost all of these deaths occur in developing countries, where lifesaving medical care may not be affordable or available to the families with the most critical needs. In addition, income loss due to the need for parents to take care of sick children can have a very significant economic burden on families that can least afford it.

29 Sep 2009

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Merck's GARDASIL receives approval from FDA Advisory Committee

Merck & Co., Inc. announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee agreed that efficacy, immunogenicity and safety data from clinical trials in males support the use of GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] in boys and men 9 through 26 years of age for the prevention of genital warts caused by human papillomavirus (HPV) types 6 and 11.

10 Sep 2009

Third human clinical trial of LigoCyte's norovirus vaccine started

LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received either the vaccine or placebo.

8 Sep 2009

Discovery of new transmission patterns may help prevent diarrhea-causing disease rotavirus

New vaccines have the potential to prevent or temper epidemics of the childhood diarrhea-causing disease rotavirus, protect the unvaccinated and raise the age at which the infection first appears in children, federal researchers reported in a study today.

16 Jul 2009

WHO recommends worldwide use of rotavirus vaccine for children

To reduce an estimated half million deaths and two million hospitalizations from diarrhea caused by rotavirus each year, the WHO on Friday recommended that oral rotavirus vaccines be added to national childhood immunization programs, broadening access to the vaccine in the developing world, Reuters reports.

5 Jun 2009